Lenalid 10mg Capsule (Lenalidomide) is an immunomodulatory drug (IMiD) extensively used in hematology-oncology for treating multiple myeloma (MM) and myelodysplastic syndromes (MDS). Composition: Each capsule contains 10mg Lenalidomide as active pharmaceutical ingredient with pharmaceutical excipients. Indications: Lenalid is prescribed as first-line induction therapy for newly diagnosed multiple myeloma, maintenance therapy post-stem cell transplantation (ASCT), treatment of relapsed/refractory multiple myeloma, and deletion 5q MDS. Clinical efficacy demonstrates improved overall survival and progression-free survival when combined with dexamethasone or bortezomib. Contraindications: Absolute contraindications include pregnancy (teratogenic/Category X), uncontrolled cardiac arrhythmias, severe hepatic disease, and hypersensitivity to lenalidomide components. Relative contraindications require specialist evaluation in patients with compromised renal function (CrCl <30mL/min), active infections, or neurological complications. Drug Interactions: Significant interactions occur with ACE inhibitors (increased hypotension), anticoagulants (warfarin, DOACs – requires INR/clotting monitoring), and medications affecting renal clearance (NSAIDs, aminoglycosides). Dosage & Administration: Typical dosing is 25mg daily on days 1-21 of 28-day cycles for MM; MDS patients receive 10mg daily. Dose adjustments required based on renal function, tolerability, and hematologic response. Storage: Lenalid capsules must be stored at 15-30°C in original, moisture-protective packaging. Side Effects: Common adverse effects include neutropenia (3-7%), thrombocytopenia (3-5%), anemia, fatigue, constipation, and peripheral neuropathy in advanced disease. Serious adverse events include deep vein thrombosis (DVT) risk requiring thromboprophylaxis, elevated liver enzymes, and cardiac events. Precautions & Warnings: Mandatory monthly CBC and comprehensive metabolic panel monitoring throughout therapy. Baseline and periodic assessment of renal function, cardiac status, and neurological examination required. All patients require thrombotic event prophylaxis (aspirin, warfarin, or LMWH) based on individual risk stratification. Pregnancy & Lactation: Lenalidomide is absolutely contraindicated in pregnancy and breastfeeding. Males taking lenalidomide must use contraception during therapy and for 28 days post-treatment. Females of childbearing potential require two forms of contraception, monthly pregnancy tests, and enrollment in mandatory Risk Evaluation and Mitigation Strategies (REMS) programs. Substitutes & Alternatives: Alternative IMiDs include Pomalidomide (Pomalyst) and Thalidomide; proteasome inhibitors include Bortezomib, Carfilzomib, and Ixazomib. Monoclonal antibodies (daratumumab, elotuzumab) provide combination approaches. FAQs: Patients commonly ask about expected response timeline (typically 2-4 cycles for initial response), management of thromboembolic complications, handling of dose modifications, and long-term maintenance therapy strategies. Treatment cost and insurance coverage varies significantly. Expected Response Timeline: Month 1-3 assessment determines tolerability; Month 3 response evaluation via bone marrow biopsy and serum M-protein; Month 6 assessment confirms complete or partial response status. Book Urgent Hematology-Oncology Consultation: Mandatory at therapy initiation for baseline risk assessment, REMS enrollment, thromboprophylaxis selection, and monitoring protocol establishment. Schedule Laboratory Tests: Baseline CBC, metabolic panel, LDH, calcium; monthly CBC during all therapy; baseline ECG; periodic renal function assessment; bone marrow evaluation at baseline and after 3-4 months.